Innovation for Global Supply
A 190-acre campus in Delaware advances WuXi STA’s mission to deliver flexible, end-to-end pharmaceutical manufacturing services worldwide.
Middleton Campus
Middleton, DE
WuXi STA, a premier contract research, development, and manufacturing organization (CRDMO), supports global pharmaceutical partners with integrated solutions for producing active pharmaceutical ingredients and drug products. To increase capacity and improve supply chain resilience, the company initiated the development of a new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware.
The campus addresses the growing demand for agile, high-quality manufacturing by consolidating services across four buildings totaling 458,000 square feet in Phase I. These include oral solid dosage (OSD), lipid nanoparticle (LNP), formulation, filling, and packaging lines, clinical research laboratories, warehousing, administrative offices, and a central utility building. The site also houses WuXi STA’s U.S. corporate headquarters, complete with offices, collaboration zones, amenities, and support spaces.
Designed to support formulation development and full-scale clinical and commercial production, the facility provides formulation development and offers full-scale clinical and commercial production capabilities. It also encompasses packaging, labeling, storage, and distribution of clinical trial materials and commercial drug products. The project enhances both flexibility and output, helping WuXi STA serve clients more reliably across global markets.
Planned for completion in 2026, the site will eventually add drug substance manufacturing through Phases II and III, further integrating development and production. At full build-out, the campus will support WuXi STA’s long-term growth while bringing approximately 500 new full-time jobs to Delaware.
Meet the Design Team
